Key result
DNA testing (genotyping) is discussed regarding its role in the diagnosis, management, and genetic screening of patients with long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome.
Why the study?
What is the role of DNA testing for diagnosis, management, and genetic screening in long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome?
Population
Patients with long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome, as well as populations…
Design
Editorial
Authors
Loading...
DNA testing for LQTS, HCM, and Marfan syndrome is of substantial interest for diagnosis and screening, though its utility is currently limited by incomplete genetic knowledge, variable expressivity, and reduced penetrance.
What is the role of DNA testing for diagnosis, management, and genetic screening in long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome?
DNA testing for LQTS, HCM, and Marfan syndrome is of substantial interest for diagnosis and screening, though its utility is currently limited by incomplete genetic knowledge, variable expressivity, and reduced penetrance.
G. Michael Vincent (2001) conducted an editorial in Long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome. DNA testing (genotyping) was evaluated. DNA testing (genotyping) is discussed regarding its role in the diagnosis, management, and genetic screening of patients with long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: